Irbesartan E Idroclorotiazide Doc Generici

Irbesartan, the active ingredient in Irbesartan E Idroclorotiazide Doc Generici, is an angiotensin II receptor blocker presented as a combined tablet for oral use. It is employed to lower elevated blood pressure and is often prescribed for adults with primary hypertension, either alone or in combination with a thiazide diuretic.

GNH USA supplies Irbesartan E Idroclorotiazide Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Irbesartan/HCTZ is indicated for conditions within the cardiovascular system, primarily to manage high blood pressure. - Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes by lowering intraglomerular pressure. - Heart failure (when combined with other therapy): assists in decreasing fluid overload and improving cardiac workload.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Increased urination: due to diuretic effect. - Electrolyte imbalance: low potassium or sodium levels. - Fatigue: general feeling of tiredness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Severe hypotension: marked drop in blood pressure causing fainting.

Before prescribing Irbesartan/HCTZ, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR prior to initiation. - Electrolyte surveillance: check potassium and sodium levels regularly. - Pregnancy avoidance: drug is contraindicated in pregnancy due to fetal risk. - Elderly caution: start at lower dose and monitor for orthostatic effects. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Irbesartan/HCTZ can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - Lithium: increased lithium levels and toxicity risk. - ACE inhibitors: additive effect on potassium and renal function.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and affect kidney function. - Other antihypertensives: additive blood pressure lowering may cause hypotension. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan plasma concentrations.